Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Nls Pharmaceutics Ltd
(NQ:
NLSP
)
4.250
-0.850 (-16.67%)
Streaming Delayed Price
Updated: 3:59 PM EDT, Oct 10, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Nls Pharmaceutics Ltd
< Previous
1
2
3
4
5
6
7
Next >
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
August 31, 2023
It's time for another breakdown of the biggest pre-market stock movers as we dive into all of the latest news for Thursday!
Via
InvestorPlace
NLS Pharmaceutics CEO Highlights Progress And Plans For Advancing Rare CNS Disorder Therapies In Shareholder Letter
August 28, 2023
NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) recently released a comprehensive shareholder letter by its CEO, Alex Zwyer, detailing recent achievements and ongoing endeavors.
Via
Benzinga
NLS Pharmaceutics CEO Issues Letter to Shareholders
August 28, 2023
Via
ACCESSWIRE
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
August 23, 2023
It's time for another dive into the biggest pre-market stock movers as we break down all of the biggest news on Wednesday!
Via
InvestorPlace
NLS Pharmaceutics Company Update and Webcast Today Postponed
June 30, 2023
Via
ACCESSWIRE
Why Universal Health Services Shares Are Trading Lower By 6%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
July 26, 2023
Gainers Silicon Motion Technology Corporation (NASDAQ: SIMO) shares climbed 78.9% to $93.40 following a report suggesting China approval of the company's Maxlinear merger.
Via
Benzinga
Why iMedia Brands Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Friday's Mid-Day Session
July 07, 2023
Gainers Prestige Wealth Inc. (NASDAQ: PWM) shares jumped 65.6% to $8.28. Prestige Wealth reported pricing of $5 million initial public offering of 1 million shares of common stock at a price of $5 per...
Via
Benzinga
NLS Pharmaceutics to Proceed with Phase 3 Clinical Program (AMAZE) for Mazindol ER for the Treatment of Narcolepsy Following FDA Review and IRB Approval of the Full Study Protocol
July 03, 2023
Via
ACCESSWIRE
NLS Pharmaceutics Releases the Results from its Annual General Meeting
June 30, 2023
Via
ACCESSWIRE
CORRECTION FROM SOURCE: NLS Pharmaceutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
June 19, 2023
Via
ACCESSWIRE
NLS Pharmaceutics Announces Company Update Webcast
June 19, 2023
Via
ACCESSWIRE
NLS Pharmaceutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
June 15, 2023
Via
ACCESSWIRE
NLS Pharmaceutics Announces Positive Safety Data From In Vitro CYP450 and Transporter Mediated Drug-Drug Interaction Studies of Mazindol
June 14, 2023
Via
ACCESSWIRE
NLS Pharmaceutics Appoints Keith Harrison Dewedoff as Interim Chief Financial Officer
May 08, 2023
Via
ACCESSWIRE
NLS Pharmaceutics Presents Latest Clinical and Preclinical Data at SLEEP 2023
May 04, 2023
Via
ACCESSWIRE
NLS Pharmaceutics Receives Green Light from the U.S. FDA to Proceed with Phase 3 Clinical Program (AMAZE) for Quilience(R) (Mazindol ER) for the Treatment of Narcolepsy
May 02, 2023
Via
ACCESSWIRE
NLS Pharmaceutics Presents Latest Preclinical Pipeline Data at American Society of Clinical Psychopharmacology
April 25, 2023
Via
ACCESSWIRE
Why Did Bullfrog AI Stock Jump More Than 50%?
April 05, 2023
Trading volume and share price for BFRG took significant leaps forward on news the digital biopharmaceutical company will partner with Johns Hopkins University.
Via
MarketBeat
Topics
Artificial Intelligence
Initial Public Offering
Exposures
Artificial Intelligence
Securities Market
NLS Pharmaceutics Announces Open Label Extension Study Six-Month Data for Quilience(R) (Mazindol ER) in the Treatment of Narcolepsy Type 1 and Type 2
March 27, 2023
Via
ACCESSWIRE
NLS Pharmaceutics to Present at the 35th Annual Roth Conference
March 01, 2023
Via
ACCESSWIRE
NLS Pharmaceutics Announces Completion of Open Label Extension Study with Quilience(R) (Mazindol ER) for the Treatment of Narcolepsy
January 30, 2023
Via
ACCESSWIRE
NLS Pharmaceutics Regains Compliance with Nasdaq Stockholders' Equity Requirement
January 25, 2023
Via
ACCESSWIRE
NLS Pharmaceutics Announces New In-Vitro Data Reconfirming Quilience's(R) (Mazindol ER) Unique Dual Mechanism of Action Involving Significant Orexin-2 Receptor Activity
January 23, 2023
Via
ACCESSWIRE
Why Calyxt Shares Are Trading Higher By Around 116%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
January 17, 2023
Gainers Celyad Oncology SA (NASDAQ: CYAD) jumped 187% to $2.30 after gaining 21% on Friday. Celyad Oncology, last month, decided to discontinue the development of its remaining clinical program...
Via
Benzinga
NLS Pharmaceutics Announces an R&D Update Webcast to Review the Company's Growing Portfolio of Pre-Clinical Compounds
January 12, 2023
Via
ACCESSWIRE
NLS Pharmaceutics Announces Compliance with Nasdaq Bid Price Requirement
January 12, 2023
Via
ACCESSWIRE
NLS Pharmaceutics to Participate in Upcoming Investor Conferences
January 11, 2023
Via
ACCESSWIRE
NLS Pharmaceutics Announces Technology Patent Grant Covering Mazindol for Treatment of Attention Deficit Hyperactivity Disorder and Rare Sleep Disorders in Hong Kong
January 10, 2023
Via
ACCESSWIRE
NLS Pharmaceutics CEO Issues Letter to Shareholders
December 22, 2022
Via
ACCESSWIRE
NLS Pharmaceutics Announces Israeli Patent Grant Covering Mazindol for Treatment of Attention Deficit Hyperactivity Disorder and Other Sleep Disorders Through 2037
December 20, 2022
Via
ACCESSWIRE
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.